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Review Article
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A review is presented of the use of developmental toxicity testing in the United States and international regulatory
assessment of human health risks associated with exposures to pharmaceuticals (human and veterinary), chemicals
(agricultural, industrial, and environmental), food additives, cosmetics, and consumer products. Developmental
toxicology data are used for prioritization and screening of pharmaceuticals and chemicals, for evaluating and labeling
of pharmaceuticals, and for characterizing hazards and risk of exposures to industrial and environmental chemicals. The
in vivo study designs utilized in hazard characterization and dose-response assessment for developmental outcomes
have not changed substantially over the past 30 years and have served the process well. Now there are opportunities to
incorporate new technologies and approaches to testing into the existing assessment paradigm, or to apply innovative
approaches to various aspects of risk assessment. Developmental toxicology testing can be enhanced by the refinement
or replacement of traditional in vivo protocols, including through the use of in vitro assays, studies conducted in
alternative nonmammalian species, the application of new technologies, and the use of in silico models. Potential
benefits to the current regulatory process include the ability to screen large numbers of chemicals quickly, with the
commitment of fewer resources than traditional toxicology studies, and to refine the risk assessment process through an
enhanced understanding of the mechanisms of developmental toxicity and their relevance to potential human risk. As
the testing paradigm evolves, the ability to use developmental toxicology data to meet diverse critical regulatory needs
must be retained. Birth Defects Res (Part B) 92:384–394, 2011. r 2011 Wiley Periodicals, Inc.
Key words: developmental toxicology testing; pharmaceuticals; environ-
mental chemicals; food additives; cosmetics; consumer products; risk
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INTRODUCTION
The assessment of developmental toxicology data is a
critical aspect of hazard evaluation for pharmaceuticals
and environmental chemicals. The International Life
Sciences Institute (ILSI) Health and Environmental
Sciences Institute (HESI) Developmental and Reproduc-
tive Toxicology Technical Committee initiated a project to
conduct a comprehensive critical review of the state of
the art for developmental toxicity testing for safety
assessment, and to explore future directions. A public
Workshop was held on April 29–30, 2009 in Washington,
DC to explore this issue in greater depth.
In this article, we describe the current status of
developmental toxicity testing within a variety of
programs and discuss other considerations that are of
significant influence on the future state of the science.
This serves as an introduction to topic papers that
provide a detailed critical evaluation of current devel-
opmental toxicity testing strategies (Carney et al., 2011),
define possible refinements of testing strategies to
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maximize relevance for human safety assessment (Brannan
et al., 2011), and discuss new approaches and technologies
for developmental toxicity testing for safety assessment
(Knudsen et al., 2011).
Developmental toxicity is defined as the study of
adverse effects on the developing organism that may
result from exposure to either parent before conception,
during prenatal development, or postnatally to the time
of sexual maturation (U.S. EPA, 1991; OECD, 2008a).
Adverse developmental effects may be detected at any
point in the lifespan of the organism. The major
manifestations of developmental toxicity are death,
structural abnormality, altered growth, and functional
deficit. Framed by this context, discussion of develop-
mental toxicity testing is obligated to address studies that
include exposures throughout any stage of development,
whether prenatal or postnatal. Thus, not only traditional
prenatal developmental toxicity studies but also repro-
ductive toxicity studies (which include exposure to
pregnant and lactating dams, as well as to neonatal and
juvenile subjects), or studies that assess functional
outcomes following exposures during critical periods of
organ system development such as the developmental
neurotoxicity study, are considered (OECD, 2007a).
Although standardized testing protocols (i.e. test guide-
lines) are often treated as if they are distinct entities, they
in fact represent a continuum of exposure and testing
during early life stages, through growth and maturation,
and across stages of primary reproductive function in
adults. Study designs for guideline developmental and
reproductive toxicity studies used for screening and
testing pharmaceuticals, industrial chemicals, and pesti-
cides are discussed and diagrammed in Tyl (2010) and
Makris (2010).
There is an increasing recognition of the possibility of
profound effects of genetic allelic diversity and of
nonchemical environmental factors (e.g. food, crowding,
isolation, mental and physical stimulation) on develop-
mental and reproductive outcomes. However, past and
current practices in study conduct have intentionally
used outbred (40 generation) or inbred (brother–sister
matings) laboratory species, with care to minimize
genetic drift and founder effects in small colonies, to
keep the genetic make up of the control and various
treatment groups the same. Study environment (tempera-
ture, relative humidity, feed, bedding, water source,
caging, etc.) is also maintained identically among all
groups to remove that source of variability. Thus, typical
animal test systems may not fully address the interactions
between/among the test chemical, the genome of the test
system, and the environment that can contribute to risk in
the heterogeneous human population. Additionally, test
substance administration to experimental animals is often
far greater than human doses (particularly for environ-
mental chemicals), and further, chemicals are generally
administered individually to test subjects in experimental
testing for regulatory purposes, while typical exposures
in humans are to chemical mixtures.
CURRENT USE OF DEVELOPMENTAL
TOXICITY DATA UNDER VARIOUS
REGULATORY PROGRAMS
The following brief description of the primary uses of
developmental toxicity data illustrates both similarities
and differences in data requirements and approaches
across various regulatory agencies. Some chemicals,
generally due to multiple applications or uses, may fall
under one or more of these categories simultaneously.
For both pharmaceuticals and environmental chemicals,
the US regulatory perspective is primarily highlighted;
however, parallel international regulatory programs are
acknowledged, and to some extent addressed in detail.
Pharmaceutical (Drugs, Biologics, and Medical
Devices)
Pharmaceuticals for human use must undergo repro-
duction toxicity testing for the purposes of hazard
identification and to aid in the evaluation of risk/benefit
to women of childbearing potential who may be treated
with the compound. The guidelines for testing pharma-
ceuticals regulated by the US FDA and the European
Medicines Agency are delineated in ICH document
S5(R2) (ICH, 2005). In the United States, reproduction
and developmental toxicity data are also needed to label
drug products according to Code of Federal Regulations
(CFR 201.57). For most compounds, the drug’s
label includes information regarding any effects on
fertility, embryo–fetal toxicity, teratogenic potential, and
peri/postnatal development.
Veterinary Pharmaceuticals
The approval process of pharmaceuticals for veter-
inary use considers not only the safety of the animals that
would receive the drug directly but also of humans who
might consume products from a treated animal (e.g.
milk, meat). To be legally marketed in the United States,
new animal drug products must be approved under a
NADA (New Animal Drug Application) by the FDA
Center for Veterinary Medicine (CVM). Legal require-
ments for NADAs are delineated in 21 CFR 514. Labeling
requirements for prescription veterinary drugs can be
found in 21 CFR 201.105. There are several guidance
documents for industry that are available from FDA/
CVM (CVM, 2006) and the International Cooperation on
Harmonisation of Technical Requirements for Registra-
tion of Veterinary Medical Products (VICH) regarding
reproductive and developmental toxicity testing of
veterinary pharmaceuticals that is needed for approval.
Target Animal Safety for Veterinary Pharmaceutical Products
(VICH GL43) discusses reproduction toxicity studies that
are required for systemically absorbed pharmaceuticals
intended for breeding animals (VICH, 2008). These
studies are to be conducted in the species for which the
drug is intended and usually are not extended past the
postnatal period unless there are specific concerns based
on the known pharmacological and/or toxicological
properties of the test article or its class. The documents-
Studies to Evaluate the Safety of Residues of Veterinary Drugs
in Human Food: Reproductive Toxicity Testing (VICH GL22)
and Studies to Evaluate the Safety of Residues of Veterinary
Drugs in Human Food: Developmental Toxicity Testing
(VICH GL32) cover veterinary pharmaceuticals that
may be present in residual amounts in animal products
intended for human food (VICH, 2004a,b). These studies
are generally conducted in rats and a multigeneration
protocol is standard.
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Chemical (Agricultural, Industrial, and
Environmental)
The chemical industry is one of the most highly
regulated industries in the United States. This is for good
reason since agricultural and chemical exposures are not
typically intended or intentional, and ubiquitous and
varied uses of these substances creates a wide variety of
exposure scenarios. The Toxic Substances Control Act
(TSCA) is the central law governing industrial chemicals.
This law enables the EPA to screen and regulate new
chemicals as they are coming on to the market, as well as
to evaluate existing chemicals. The Federal Insecticide,
Fungicide, and Rodenticide Act (FIFRA) is the primary
law governing agricultural chemicals in the United States
In accordance with this statute, pesticide products must
be registered with EPA before manufacture, transport, or
sale. Under FIFRA, chemicals are developed based on
their biological activity (i.e. pesticides), whereas under
TSCA, chemicals are developed based on their physical
and chemical properties (e.g. paints, adhesives, films,
cleansers, plasticizers); hence, the requirements for
Registration under FIFRA are very different that the
requirements for a pre-manufacturing notice (PMN)
under TSCA. For a FIFRA registration of chemicals, the
requirements are stringent and voluminous. Required
studies are designed to assess toxicokinetics, environ-
mental fate (migration into soil, ground water, air),
efficacy in the target species, and toxicity into nontarget
species. Toxicology studies range from acute, to sub-
chronic, and through chronic/carcinogenicity studies, as
well as including studies that address specific organ
systems or biological processes, thereby providing
adequate screening for systemic, reproductive, develop-
mental, genetic and other toxicities in a broad array of
test systems. For a TSCA PMN to begin production/
importation of a chemical, the requirements are relatively
minimal; any toxicity data must be submitted, at least an
LD50 (median lethal dose) study, the proposed use, and
the proposed amount to be manufactured/imported
(production volume) the first year. For some chemicals,
a more extensive toxicological database may be sub-
mitted at this stage, especially for chemicals that are
intended to be produced in high volume and/or for
which exposure is predicted to be widespread. Under
TSCA, the EPA has 90 days to accept or reject the PMN;
only literature searches and/or structure–activity rela-
tionships are usually conducted by the Agency. Once the
PMN has been granted under TSCA, the EPA can request
(via negotiated test agreements) or require (via test rules)
specific studies for specific chemicals, typically based on
exposures. If the chemical, after the PMN is approved,
will have additional uses, the manufacturer/importer
will have to submit a Significant New Use Request, again
with submission of minimum data and no required
toxicology. Test guidelines that are utilized in develop-
mental and reproductive toxicity testing for both
industrial chemicals under TSCA and pesticides under
FIFRA have been harmonized by the EPA Office of
Prevention, Pesticides, and Toxic Substances (OPPTS). In
addition, OPPTS has harmonized their toxicity testing
guidelines with the multinational Organisation of Eco-
nomic Co-operation and Development (OECD). The
harmonized guidelines are listed in Table 1. Although
OECD member countries have agreed to accept, in
principle, studies conducted according to OECD guide-
lines, there may also be specific extant national regula-
tions that define or modify the use of these guidelines in
chemical testing (e.g. the Japanese Ministry of Agricul-
ture, Forestry, and Fisheries [MAFF]).
Food Additives
The US FDA is the agency responsible for ensuring
that the direct food additives and color additives used in
food are safe for all consumers. The US FDA issued the
Toxicological Principles for the Safety Assessment of Direct
Food Additives and Color Additives Used in Foods, com-
monly referred to as the Redbook I (1982) and the
Redbook II (1993). The FDA Center for Food Safety and
Applied Nutrition (CFSAN) requires a prenatal devel-
opmental toxicity study and a multigeneration reproduc-
tion study for an adequate safety assessment of food
ingredients (Collins et al., 2006; U.S. FDA, 2000a,b).
In the European Union, overall regulation for food-
stuffs in human consumption is found in Regulation (EC)
178/2002 [OJ L 31, February 1, 2002] (EC, 2002). Food
additives are regulated under Council Directive 89/107/
EEC [OJ L 40, February 11, 1989] on the approximation of
the laws of the Member States concerning food additives
authorized for use in foodstuffs intended for human
consumption (EC, 1989).
Cosmetics
Although cosmetics are regulated by the FDA in the
United States, the legal authority is different from other
products regulated by the agency, such as drugs,
biologics, and medical devices. With the exception of
color additives, cosmetic products and ingredients are
Table 1
Harmonized Guidelines Used in Screening and Testing for Developmental and Reproductive Toxicities for US EPA and
OECD
Guideline US EPA OECD
Prenatal developmental toxicity OPPTS 870.3700 (U.S. EPA, 1998a) GL 414 (OECD, 2001a)
Reproduction and fertility effects OPPTS 870.3800 (U.S. EPA, 1998b) GL 416 (OECD, 2001b)
One-generation reproductive toxicity study N/A GL 415 (OECD, 1983)
Reproduction/developmental toxicity screening test OPPTS 870.3550 (U.S. EPA, 2000a) GL 421 (OECD, 1995)
Combined repeat dose toxicity study with the
reproduction/developmental screening test
OPPTS 870.3650 (U.S. EPA, 2000b) GL 422 (OECD, 1996)
Developmental neurotoxicity OPPTS 870.6300 (U.S. EPA, 1998c) GL 426 (OECD, 2007a)
OECD, Organisation of Economic Co-operation and Development; OPPTS, Office of Prevention, Pesticides, and Toxic Substances.
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not subject to FDA premarket approval authority. The
Office of Cosmetics in CFSAN follows the Redbook
guidelines for their required reproductive and develop-
mental studies (U.S. FDA, 2005a). In Europe, the
manufacturers have traditionally followed the OECD
guidelines.
In Europe, the components of cosmetics are primarily
regulated under Council Directive 76/768/EEC [OJ L
262, September 27, 1976] on the approximation of the
laws of the Member States relating to cosmetic products
and its subsequent amendments (EC, 1976).
Global harmonization for cosmetics regulation is
guided by the International Cooperation on Cosmetic
Regulation (ICCR) whose members include the United
States (FDA/CFSAN), Japan (MHW), the EU (European
Commission DG Enterprise and Industry), and Canada
(Health Canada) (U.S. FDA, 2010). The purpose of this
group is to ensure global consumer protection, and to
minimize barriers to international trade.
Consumer Products
The Consumer Product Safety Commission (CPSC) is an
independent federal regulatory agency charged with
protecting the public from unreasonable risks from thou-
sands of types of consumer products. The CPSC administers
and enforces several laws including the Consumer Product
Safety Act, the Consumer Product Safety Improvement Act,
and the Federal Hazardous Substances Act (FHSA) (CPSC,
2008a,b,c). In 1992, the Commission finalized the Chronic
Hazard Guidelines (CHG), to be used for determining
whether customary or reasonably foreseeable handling or
use of products subject to the FHSA would present a
chronic hazard by containing a carcinogen, neurotoxicant,
or reproductive or developmental toxicant (CPSC, 1992).
The guidelines also explain certain principles to be used in
evaluating the risk resulting from exposure to such
products. Although the guidelines are not mandatory and
the FHSA does not provide for premarket approval of
consumer products, such products subject to the FHSA are
expected to be appropriately labeled if they present a
chronic hazard, and are subject to enforcement action if they
do not carry such a label. No toxicity or exposure testing is
required under the FHSA; thus, the CHG are meant to
provide general guidance for the evaluation of data by
manufacturers and other interested parties for determina-
tion of whether a substance is toxic. In practice, CPSC staff
scientists consult other guidance in their determinations,
which generally undergo external peer review.
Section D of the CHG (p 46,641–46,644) discusses the
evaluation of reproductive and developmental toxicity
based on human and animal data. It addresses acceptable
risks to children and adults, and discusses definitions of
‘‘sufficient’’ and ‘‘limited’’ evidence of developmental
and reproductive toxicity from human and animal
studies as well as the categories of ‘‘known,’’ ‘‘probable,’’
or ‘‘possible’’ developmental and reproductive toxicants.
DIFFERENCES IN REGULATORY
PERSPECTIVE (‘‘ONE SIZE DOES NOT FIT
ALL’’)
Although the traditional developmental toxicity test
data that are assessed and incorporated into decision-
making are virtually identical across the various
regulatory organizations, there can be very distinct
differences in the way that the data are utilized. The
impact of developmental toxicity findings is linked to the
mission of each Agency. For example, the EPA utilizes
these data to assess potential risks to the human
population from exposure to various environmental
pollutants, focusing on dose levels that do not result in
adverse effects. On the other hand, FDA assesses
pharmaceuticals, which generally have some pharmaco-
logic benefit to the target population, and regulatory
decision-making for pharmaceuticals must address both
the benefits and the risks. Additionally, there are
differences in the exposures that must be considered
across agencies. For environmental pollutants, exposures
are generally inadvertent, whereas for pharmaceuticals,
exposures are deliberate. The health and/or suscept-
ibility status of exposed populations may also vary
widely. For pharmaceuticals, it is more likely that the
health of the individuals being treated has been
compromised, whereas that may or may not be the case
for those individuals exposed to environmental contami-
nants. Finally, the developmental toxicity test data under
consideration may be used to screen for adverse
outcomes and doses, or they may be used for an in-
depth characterization of the toxicological profile of the
chemical.
THE USE OF DEVELOPMENTAL
TOXICITY DATA
Prioritization and Screening
Pharmaceuticals. The capabilities for early screen-
ing of drug candidates for potential developmental
toxicity have evolved tremendously in the last several
years and such assays are becoming a regular part of the
extensive process of selection of optimal molecules to be
advanced for registration and use as medicine. As in all
screening processes, the developmental toxicity assays
selected for use must have high throughput capabilities
and deliver data quickly with precision and reliability to
enable differentiation [prioritization] of compounds. Test
systems, such as whole embryo culture, zebra fish and
stem cell cultures, whose developmental responses are
well characterized have the potential to be used in
combination with other screening assays to generate data
that allow for comparative analysis of toxic potency.
These data contribute to an overall evaluation of a drug
candidate and may signal deselection of that particular
molecule [or class of molecules] from further evaluation.
More often, however, the data from early screening alerts
a company to a potential developmental risk. In such
cases, the subsequent developmental studies can be
modified, or focused, or mechanistic studies can be
devised, to better assess that potential risk. These assays
can aid in compound selection early in the drug
development process but they will not replace the more
thorough regulatory testing that must occur for a drug to
be approved for use [See previous section].
Chemicals. Novel chemicals are typically evalu-
ated in preliminary screening studies. The purposes of
screening studies are multiple and often include con-
sideration for early stage product deselection in the event
that adverse events are detected in the screening
evaluation. Early detection of adverse effects can
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ultimately minimize the numbers of animals used in
testing as well as the costs associated with the safety
assessment program for a particular chemical. Screening
studies can be designed such that several related
substances are tested simultaneously with a shared
control group. This approach permits comparison of
potency among related substances, uses fewer animals
by sharing the control group data across the substances,
and could ultimately reduce cycle time in the product
development process.
Industrial chemicals are used due to their physical
chemical properties (e.g. solvent), position within a
reaction sequence (e.g. monomer for polymer produc-
tion), or due to other specific properties crucial to an
industrial process (e.g. catalysts). Unlike pesticides or
pharmaceutical agents, industrial chemicals are not
designed to be biologically active. The level of testing
for developmental toxicity endpoints is usually deter-
mined by the extent of human exposure, structural alerts,
or by the presence of other toxicity characteristics (e.g.
mutagenicity). The extent of human exposure for many
industrial chemicals is often difficult to quantify so
production/import volume is used as a rough predictor
of human exposure. Consideration of use and exposure
are made for site-restricted industrial intermediates.
Chemicals that are produced in large amounts but are
primarily restricted to use within industrial plants can be
tested in screening studies for developmental endpoints.
Examples of these study types are the OPPTS 870.3550/
OECD 421 and OPPTS 870.3650/OECD 422 (Makris,
2010).
Under the recent EU Registration, Evaluation, Author-
isation, and Restriction of Chemicals (REACh) legislation,
screening studies for developmental toxicity are required
under Annex VIII for all substances manufactured or
imported in quantities of 10 tonnes or more (Article
12(1)(c)). OECD guideline studies 421 or 422 are required
if there is no evidence from structurally related sub-
stances, QSAR estimates, or from in vitro methods that
the substance may be a developmental toxicant. These
studies do not need to be conducted if the chemical is a
genotoxic carcinogen or a germ cell mutagen and
appropriate risk management measures are implemented.
In cases where relevant human exposures can be
excluded or if guideline reproductive (OPPTS 870.3800
or OECD 416) and developmental (OPPTS 870.3700 or
OECD 414) toxicity studies are available, the screening
studies do not need to be performed. If available data
indicate that the substance is a reproductive toxicant
(Category 1 or 2, R60 C&L), then testing for develop-
mental toxicity should be considered. If the registrant of
the chemical has serious concerns about potential adverse
effects on development, the registrant may propose the
definitive studies (OPPTS 870.3700 or OECD 414) instead
of the screening studies.
Issues That Should be Considered or Addressed
in Developmental Toxicity Testing
Translational medicine, cross-species extrapo-
lation. Ideally, the data obtained to determine the
reproductive and developmental toxicity of a compound
are derived from animal and/or other nonhuman models
before human exposure. Thus, it is critical that the
endpoints monitored in our models have relevance for
the human condition. These might include metrics of
fertility, sexual differentiation and development, etc. The
need to relate findings from preclinical models with
human outcome suggests that the endpoints used in our
models should be validated, i.e. shown to demonstrate
some direct correlation with human outcomes. The fact
that this has not historically been the case may account
for some past failures of animal models to predict
adverse human outcome. The lack of detection of the
teratogenic effects of thalidomide in animal models is but
one example (Schardein, 1998). Future efforts should
involve concerted validation efforts, particularly in the
case of in vitro and in silico systems, to maximize their
utility and predictivity. In the case of whole animal
models, it will be critical to utilize the exact same
(homologous) endpoints of interest to humans, where
possible, or to at least use endpoints (analogues) that
correlate with human endpoints or are otherwise
predictive. For science to best serve public health needs,
data obtained in animal models must be extrapolatable
and relevant to humans.
Mode of action data. It is also critical to employ
models that metabolize test compounds and exhibit the
appropriate pathways and modes of action (e.g. receptor
interactions) that are relevant to humans. If, for example,
a compound’s mechanism/mode of toxic action involves
a specific pathway(s) (e.g. oxidative phosphorylation,
protein synthesis, apoptosis) or receptor(s) (e.g. gluta-
mate, dopamine, aromatic hydrocarbon), then the model
used to screen for toxicity should also share those
pathways and/or receptors with humans.
Cumulative exposure issues. In real world situa-
tions, humans are often exposed to a given chemical
repeatedly and at various life stages. Clearly, acute single
exposures to high doses of chemicals can lead to frank
poisonings and are of obvious regulatory concern.
However, repeated and/or continuous exposures to
relatively low doses of compounds or exposures to
different chemicals concurrently (i.e. mixtures) or
sequentially are often the rules rather than the exceptions
and pose more difficult problems for developmental
toxicity risk assessment. Experimental designs and
approaches to risk assessment should take into consid-
eration the cumulative effects of exposure, many of
which can vary depending upon the life cycle stage
during which such exposures occur. As a noteworthy
example, descriptions of historical testing strategies and
an approach to the risk assessment of developmental
outcomes resulting from cumulative exposures to multi-
ple phthalate ester chemicals are addressed in a report by
the National Research Council (NRC, 2008b).
Critical windows of exposure and effect. In
addition to cumulative effects, the life stage at exposure
can be extremely critical. There are periods during
development in which organisms may be extremely
sensitive to chemical exposure. Organs develop at
different times and rates and are often exquisitely
sensitive to disruption by chemical exposure during this
time. Thus, exposure to compounds such as anesthetic
agents, alcohol, lead, and other compounds during
gestation and/or early postnatal life when organ systems
are rapidly developing can have devastating conse-
quences, whereas similar exposures in adults may be
relatively innocuous. This issue must continue to figure
large in future testing strategies.
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Latency of response. The effects of a toxic
insult(s) may not be evident until long after an exposure
occurs. For example, treatment of pregnant women with
diethylstilbesterol, an estrogen replacement therapy,
leads to concomitant fetal exposure in utero. Subsequent
cervical cancer developed in some offspring but not until
the onset of sexual maturity (Hatch et al., 1998). Efforts to
determine the developmental effects of many com-
pounds to which children are exposed (i.e. anesthetics,
methyl mercury) have demonstrated clear, primarily
functional, adverse effects that become evident as the
child develops. Adults exposed to chemicals that destroy
the neurotransmitter dopamine can lead to the eventual
development of Parkinson’s disease, a process that may
take years or decades.
Structural vs. functional outcomes. Alterations
in the structure of an organism (classic terata, tumors) are
relatively easy to find and measure. Changes in function,
however, can be much more difficult to detect. This is
particularly true for the nervous system since function
can be altered sometimes in the absence of detectable
structural changes. This necessitates the use of a broad
range of assessments or test batteries in efforts to monitor
as many functional domains as practicable. It is very
clear that animals (and humans) that are physically
normal may suffer significant functional abnormalities.
Pharmaceutical Testing and Labeling
Proposed labeling requirements. Currently,
human drug products are assigned a pregnancy category
(A, B, C, D, or X) (Kweder, 2008), but there is a proposal
(U.S. FDA, 2008) to modify the label requirements in the
CFR to eliminate pregnancy categories and put a greater
emphasis on the inclusion of human data when available.
The Final Rule for the pregnancy and lactation subsec-
tions of drug labeling is in the writing and clearance
process. Data from animal studies would still be
included in the modified drug label, and this initiative
would not change the types and amount of animal data
that are generally submitted for a drug product.
Pediatric pharmaceuticals. Reproductive toxicity
data can be helpful in identifying products that may have
different toxicity profiles in adult vs. juvenile popula-
tions (U.S. FDA, 2006). These data are used in conjunc-
tion with other information (e.g. data from adult animals
and humans, knowledge that previously identified target
organs of toxicity are undergoing significant growth and
development when the drug will be used in children) to
determine whether specialized juvenile animal studies
are needed for a product. In some circumstances,
modified peri/postnatal study designs may be used to
fulfill testing needs to explore the potential for a drug’s
toxicity in juveniles.
Industrial Chemicals and Environmental
Pollutants
Current and future testing of chemicals for develop-
mental toxicity endpoints will be influenced by regula-
tory and government programs, as these factors control
the requirements and prioritization of testing programs.
The testing of industrial chemicals or chemicals that
either end up in or are used to produce items common to
modern lifestyles is influenced by several ongoing
programs. It should be noted that the testing of industrial
chemicals for developmental toxicity endpoints is truly a
daunting task, as the number of different chemicals used
in commerce is in the tens of thousands.
Examples of these programs include the efforts
currently ongoing with the OECD Screening Information
Data Sets and EPA High Production Volume programs.
Both of these programs include evaluation of chemicals
for the potential to cause developmental toxicity as a
required endpoint. Examples of how this endpoint can be
evaluated include data from guideline studies, data from
surrogate or related materials, and data from ‘‘screening’’
studies. Typically, however, the endpoint is evaluated
using data from a guideline study (OECD Guideline 414,
421, or 422, or OPPTS 870.3700) in a single species. In
certain instances for well-studied materials (typically
very high production volume and significant human
exposure potential), data are also available for develop-
mental toxicity endpoints collected from multigenera-
tional studies.
Another example of a regulatory program that can lead
to testing of industrial chemicals for developmental
toxicity endpoints is the REAcH chemical registration
process within the European Union (EU) (EC, 2006), as
described above. With the advent of the REACh program
within the EU, many additional chemicals will be
considered and evaluated for developmental and repro-
ductive toxicity endpoints. It is important to note that the
REACh legislation specifically encourages the use of in
vitro or alternative (i.e. non-in vivo) test methods when
possible, although it is not known to what extent
alternative developmental toxicity tests are accepted by
the European Chemicals Agency.
There are programs that use developmental toxicity
data for labeling or listing of chemicals based on intrinsic
hazard information, without regard to issues of exposure
or risk. These include the Global Harmonized System
(GHS) for classification and labeling (C&L) and the
California Proposition (Prop) 65. Some impacts of these
hazard-based systems are described in the following
examples.
The use of developmental toxicity testing data in
assigning classification and labeling statements to
Material Safety Data Sheets (MSDS) and packaging is a
universal requirement for all industrial chemicals. The
recent adoption of the GHS for classification and labeling
has led to specific criteria for evaluating developmental
toxicity data for the purposes of preparing MSDS and
packaging labels. Although the GHS criteria are open to
differing interpretations, it is readily apparent that
developmental toxicity data are required to be consid-
ered as part of a labeling and classification effort. In
addition, many countries are requiring that any GHS
decision-making processes conducted by individual
companies be available for review by regulatory agencies
and the public.
Finally, the end results of developmental toxicity
testing can and do lead to chemicals being considered
for inclusion on lists of developmental toxicants by
regulatory agencies, (e.g. the Prop 65 list in California;
CalEPA, 2003). The use of the Prop 65 list in additional
regulatory activity (e.g. the California Safe Cosmetics
Program; CDPH, 2005) leads to consumer products being
surveyed for chemicals with positive developmental
toxicity findings, irrespective of exposure or risk levels
or route of exposure considerations. For example,
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ethylene glycol is listed as a developmental toxicant
by the California Safe Cosmetics Program, based upon
an evaluation in a Center for Evaluation of Risks to
Human Reproduction (CERHR) monograph (NTP,
2004a). However, the list does not explain that the
CERHR monograph limits the concerns for develop-
mental toxicity to high oral dosing regimens and
specifically excludes concerns for dermal exposure (an
exposure route of significance for the vast majority of
cosmetic products). Since inclusion on the Prop 65 list
and California Safe Cosmetics Program list invariably
affects chemical use and product deselection, it is
understandable how concerns with the way develop-
mental toxicity data are used can influence decisions on
if, when, and how developmental toxicity testing is
conducted.
Agricultural Chemicals
For agricultural chemicals, screening and testing for
developmental and reproductive toxicities are strictly
defined in 40 CFR Part 158. Yet, opportunities to utilize
new data or new approaches for the assessment of
specific issues are evident.
The Food Quality Protection Act (1996) required
(among other things) the assessment of inert pesticide
ingredients and endocrine disrupting chemicals. Both of
these efforts were monumental in scope, and approaches
have been developed to address these issues, both of
which require an adequate screening level assessment of
developmental and reproductive toxicity. For inerts, the
use of the OPPTS 870.3550/OECD 421 and the OPPTS
870.3650/OECD 422 screening studies was considered
sufficient for a screening level assessment.
For endocrine-disrupting chemicals, a separate screening
and testing program was developed in an international
collaborative effort. It included defining and validating
protocols that could be utilized in a tiered testing
scheme, to identify and characterize endocrine disruptive
effects. The testing required by this program overlaps
some of the current guideline studies (e.g. the two-
generation reproduction study), although it necessitates
the collection of even more information. Thus, the
development of a replacement protocol is under con-
sideration. Such a protocol was proposed by an ILSI-
HESI Agricultural Chemical Safety Association effort
(Cooper et al., 2006), and this protocol is now undergoing
an international discussion as an ‘‘extended one genera-
tion study’’ that incorporates the additional endocrine
endpoints of concern while reducing study duration and
maximizing animal use.
CRITICAL ISSUES AND FUTURE DIRECTIONS
The future direction of toxicity testing in general has
been a topic of intense discussion, as illustrated in a 2007
report by the National Research Council (NRC) described
below. A number of specific issues and topics have been
raised. These address such diverse issues as new types of
exposure and delivery systems (e.g. from nanotechnol-
ogy), new ways to assess exposure and effects from
changes in the genome, transcriptome, proteome, or
metabolome, better use (and organization of) existing
and new databases/registries, and the development and
use of consistent harmonized terminology, so
information can be entered, exchanged, extracted, and
used across databases, disciplines, and sources.
The Need for a Transformation of the
Developmental Toxicology Testing Paradigm
Currently, regulatory agencies rely on the use of
developmental toxicity studies in experimental animal
models. The historical path taken has generally been
either to make incremental modifications to existing tests
(e.g. for the testing of monoclonal antibodies) or to add
additional tests to cover endpoints not previously
considered (e.g. developmental neurotoxicity). This
approach has led over time to a continual increase in
the number of tests, cost of testing, use of laboratory
animals, and time to develop and review the resulting
data. Similarly, the translation and application of such
data in risk assessment has been limited by an
incomplete understanding of the extent and mechanisms
by which chemicals pose hazards to human health. For
some substances, such as nanomaterials (i.e. particles of
100 nm or less in size that are already being used in
diverse pharmaceutical, cosmetic, and environmental
applications), unique concerns regarding test substance
administration and the assessment of effects on repro-
duction and the developing fetus may need to be
addressed in novel ways. This remains an area of
preliminary research that may benefit from consideration
of a new testing paradigm (NRC, 2008a). Moreover, the
application of current risk assessment approaches to
meet existing, and evolving, regulatory needs has
encountered challenges in accommodating increasingly
complex issues (e.g. life-stage sensitivity, mixtures,
varying exposure scenarios, cumulative risk, under-
standing mechanisms of toxicity and their implications
in assessing dose-response, and characterization of
uncertainty).
Recognizing these limitations in traditional develop-
mental toxicity testing and toxicity testing in general, a
report by the NRC on ‘‘Toxicity Testing in the 21st Century:
a Vision and a Strategy’’ recommends a landmark
transformation in toxicity testing and risk assessment
that will focus on toxicity pathways (NRC, 2007b). This
approach uses the rapidly evolving scientific under-
standing of how genes, proteins, and small molecules
interact to maintain normal cell function to then
determine how some of these interactions can be
perturbed by exposure to environmental agents with
subsequent events following a toxicity pathway(s) that
may eventually lead to adverse health effects. The NRC
notes that successful application of new scientific tools in
computational, informational, and molecular sciences
will inform and produce more credible decision-making
with an increased efficiency in design and costs and a
reduction in animal usage.
Many regulatory agencies have recognized the need
for this transformative shift and have initiated research
programs to achieve the vision and goals laid out by the
NRC. These include the NIEHS NTP Roadmap for the
21st Century (NTP, 2004b) and the FDA Critical Path
Initiative (FDA, 2004; Woodcock and Woolsey, 2008). EPA
created the National Center for Computational Toxicology
(NCCT) in 2005 and launched the ToxCastTM research
program in 2006 (Dix et al., 2007; U.S. EPA, 2007). The
OECD initiated a Molecular Screening for Characterizing
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Individual Chemicals and Chemical Categories Project in
2007, published a monograph on a 2007 Workshop on
Integrated Approaches for Testing and Assessment
(OECD, 2008b), and actively utilizes Test Guideline
Committees and a QSAR Expert Group to ensure global
harmonization and validation (OECD, 2005, 2007b) of any
new approaches.
Alternative In Vitro and Nonmammalian In Vivo
Models for Developmental Toxicity Screening
The use of alternative in vitro or nonmammalian
in vivo models for general or organ/system specific
developmental toxicity screening has been a topic of
research for the past 30 years. Test systems utilizing cell-,
organ-, and embryo-cultures are available (Piersma,
2006) and are used extensively in research. Alternative
models that are considered to be validated for regulatory
screening by the European Centre for the Validation of
Alternative Methods include the embryonic stem cell
test, the limb bud micromass, and the rat postimplanta-
tion whole embryo culture. In vivo nonmammalian
models are also available for developmental toxicity
screening. Examples of alternative species that are
utilized in morphological and/or functional develop-
mental assessments and/or in mechanistic studies
include invertebrates such as the nematode (Caenorhabditis
elegans) and fruit fly (Drosophila melanogaster), and verte-
brates such as the frog (Xenopus laevis) and zebrafish
(Danio rerio) (Lein et al., 2005). It is recognized that data
derived from these alternative species can potentially have
a critical role in developmental toxicity risk assessment
(NRC, 2000).
–Omics Technologies
–Omics technology is a very exciting new frontier with
major initiatives in developmental and reproductive
toxicology. The broad term of –omics is used to describe
the following technologies:
A. Genomics, which characterizes the genes which are
up-regulated (transcribed) or down-regulated, typi-
cally immediately after an exposure in a particular
tissue, at a particular time, relative to an untreated
sample; the body of transcribed mRNAs is termed the
‘‘transcriptome’’;
B. Proteomics, which characterizes the proteins upregu-
lated (increased translation) or downregulated, typi-
cally immediately after an exposure in a particular
tissue, at a particular time, relative to an untreated
sample; the body of translated proteins is termed the
‘‘proteome’’;
C. Metabolomics, which characterizes the profile of
endogenous small molecular weight metabolites in a
body fluid (serum, urine, amniotic fluid, milk, etc.) or
in a supernatant of a homogenate from a particular
tissue, body part, embryo, etc., immediately or long
after an exposure, relative to an untreated sample; the
body of endogenous metabolites present is termed the
‘‘metabolome.’’
These techniques have been used to characterize the
early molecular responses of an embryo or fetal organ to
chemical exposure through the use of genomics or
proteomics, or to characterize the immediate or long
term alterations in the profile of endogenous metabolites
through the use of metabolomics (e.g. after in vivo or in
vitro exposure to an estrogen or antiandrogen). The data
can be used to inform mechanism, to distinguish exposed
vs. nonexposed subjects or affected vs. unaffected
subjects, even long after the exposure has ceased, or to
identify subjects with or without a disease or genetic
lesion. Such information, especially early in the disease
progression or early in the lifetime of the genetically
affected individuals, may be important in initiating
interventions as soon as possible to improve outcomes.
Pharmaceuticals. Pharmacogenomic data can be
used to screen pharmaceutical candidates as part of early
research and development. These data are not required
to be submitted to FDA, but they may be submitted
under the Voluntary Genomic Data Submission program
(U.S. FDA, 2005b). The potential for the application of
such data in personalized health care has also been
recognized, and early initiatives are being implemented
(U.S. HHS, 2008).
Environmental agents. The potential uses of
–omics data in predictive toxicology and risk assessment
for environmental agents, as well as the research and
tools that might be needed to implement such a change
in paradigm, has been considered in some detail (NRC,
2007a). Applications of this information to hazard
screening, the analysis of variation in human suscept-
ibility, the study of mechanisms of action, evaluation of
dose–response relationships, cross-species extrapolation,
and exposure assessment (including to mixtures) have
been discussed in some detail, and there are many
on-going research efforts in these areas. The NRC report
has specifically recognized an important role for –omics
data in characterizing the risk from exposures that occur
during development.
Need for Accessibility to Existing Data (Animal
and Human)
It is recognized that as new technologies and bioinfor-
matic methods are utilized, there needs to be a shift
toward increased sharing of data. This concept has been
raised in relation to –omics data (NRC, 2007a), and there
are already a number of research efforts that allow global
access to information (e.g. the ILSI-HESI toxicogenomics
project and ToxCastTM) (ILSI-HESI, 2004; Judson et al.,
2009). This concept of data sharing has been incorporated
into the REACh program as well, which requires that
toxicological data be made publicly available (EC, 2006).
Similarly, human clinical trials must be publicly
recorded on a number of websites in the United States
and European Union. ClinicalTrials.gov (http://
www.clinicaltrials.gov/), maintained by the NIH, is a
registry of clinical trials listing information about a trial’s
purpose, who may participate, and other information
pertinent to the trial conduct. The European Clinical
Trials is known as EudraCT (European Union Drug
Regulating Authorities Clinical Trials) (http://
www.dkma.dk/1024/visUKLSArtikel.asp?artikelID53321)
and is a database of all clinical trials in the EU. The
EudraCT database was established in May 2004 in
accordance with Directive 2001/20/EC. The Interna-
tional Federation of Pharmaceutical Manufacturers and
Associations Clinical Trials Portal (http://clinicaltrials.
ifpma.org/no_cache/en/myportal/index.htm) is a
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voluntary database that provides information on clinical
trials, clinical trial results, and related issues.
Complementary to this issue of globally available data
is the need for consistent and universally accepted
terminology for characterizing effects. Historically, the
developmental toxicology community has embraced this
concept, with international collaborative projects and
publications on terminology used in the evaluation of
fetal specimens (e.g. Wise et al., 1997; Makris et al., 2009).
This same attention to consistency and precision in
terminology must also be applied to new technologies for
developmental toxicity testing.
Importance of Pregnancy Registries
The FDA Center for Drug Evaluation and Research
encourages the establishment of pregnancy registries for
products that are likely to be used during pregnancy to
treat new or chronic conditions (U.S. FDA, 2002).
Pregnancy registries may also be useful for products
that are widely used in women of childbearing age, as an
inadvertent exposure during pregnancy is common.
When concerns regarding a product’s potential harm
are elevated due to data from animal studies, structure–
activity relationships, membership in a pharmacological
class known to be reproductive or developmental
toxicants, or human case reports, there is a heightened
need to establish a pregnancy registry. They can be
required as a condition of approval (e.g. a post marketing
requirement) for products that are seen as having a
potential risk of reproductive or developmental toxicity.
Pregnancy registries are important tools for collecting
human data to assess the risks and benefits of using a
given medication. Data gained through pregnancy
registries can be included in drug product labels.
Well-designed pregnancy registries enroll women ex-
posed to the drug or drugs of interest, and can evaluate a
range of developmental outcomes within a single study
and provide estimations of absolute risk for a particular
outcome. Such information is needed when counseling
women about the risks related to drug exposure. It is
important to note, however, that pregnancy registries
have limitations. Pregnancy registries generally do not
have enough statistical power to evaluate rate outcomes,
and unless the sizes of the registries are very large, they
are limited in the ability to detect modest increases in risk
for a specific malformation. Outcomes that do not
manifest until late after birth (such as deficits in behavior
or intellectual development) are often not captured.
DISCUSSION/SUMMARY/CONCLUSIONS
This article presents a broad overview of the use of
developmental toxicity testing in the assessment of
human health risks associated with exposures to phar-
maceuticals (human and veterinary), chemicals (agricul-
tural, industrial, and environmental), food additives,
cosmetics, and consumer products. It is evident that
developmental toxicology data are utilized extensively to
meet the regulatory mandates of a number of United
States agencies at the federal and state levels, as well as
serving the diverse requirements of multiple interna-
tional organizations. These data are used for prioritiza-
tion and screening for pharmaceuticals and chemicals,
for evaluating and labeling of pharmaceuticals for adults
and children, and for characterizing hazards and risk of
exposures to industrial and environmental chemicals
(including hazard labeling).
The approaches to developmental toxicity assessment,
primarily using standardized protocols that assess apical
endpoints in studies that include dose levels that exceed
expected relevant human exposures, have existed for
many decades. The in vivo study designs utilized in
hazard characterization and dose–response assessment
for developmental outcomes have not changed substan-
tially over the past 30 years. Now however, there are
opportunities to incorporate new technologies and
approaches to testing into the existing assessment
paradigm, or to apply innovative approaches to various
aspects of risk assessment, as recommended by the
National Research Council (NRC, 2007b, 2008b, 2009).
Efforts are already in place at a number of United States
and international regulatory agencies to facilitate the
implementation of this concept.
As an expansion of the developmental toxicity testing
paradigm occurs, the fact that the data are used for many
diverse purposes requires careful consideration. It will be
important to maintain the ability to use developmental
toxicity data to meet the various critical regulatory needs
highlighted in this article. Currently, the common
primary use of in vivo developmental toxicity data is
in hazard identification or characterization and dose–
response assessment. Opportunities abound to move into
new directions, including through the use of in vitro
assays, studies conducted in alternative nonmammalian
species, the application of new technologies, and in the
use of in silico models. In some cases, these new methods
will enhance the information already gleaned from in
vivo assays. One example might be in the elucidation of
mode of action information that may be useful to inform
risk assessors about the human relevance of develop-
mental toxicity observed in laboratory animals.
The potential for complete replacement of in vivo
animal testing is a lofty and commendable goal that has
been established to address ethical principles and in
some cases (e.g. REACh), a legislative directive.
A significant amount of work needs to be accomplished
to translate this concept into reality. For a successful
outcome, there needs to be a discernable link establi-
shed between cross-discipline research planning and
implementation and the needs of the risk assessment
community. As part of this effort, validation of assays
and approaches is critical. Assay reliability, reproduci-
bility, and predictivity will need to be demonstrated
through a concerted validation effort. Also of critical
importance is the establishment of links between assays
and what are considered adverse outcomes in the species
of interest; in some cases, it may only be possible to do so
in a qualitative (i.e. not quantitative) manner. Realisti-
cally, the validation process is not an insignificant task,
and it will likely require extensive human, temporal, and
capital resources.
In summary, it is evident that there is significant
opportunity and promise in the alternative models and
new technologies available for the assessment of devel-
opmental toxicology for risk assessment. Potential
benefits to the current regulatory process include the
ability to screen large numbers of chemicals quickly, and
with the commitment of fewer resources than traditional
toxicology studies, and to refine the risk assessment
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process through a greater understanding of the mechan-
isms of developmental toxicity and their relevance to
potential human risk.
ACKNOWLEDGMENTS
The authors declare that they have no competing
financial interest. We express our appreciation to Patricia
Bittner (U.S. Consumer Products Safety Commission) for
review and comment. The views expressed in this
document are those of the authors and do not necessarily
reflect the views or policies of the U.S. Environmental
Protection Agency or the U.S. Food and Drug
Administration.
REFERENCES
Brannan K, Fenton S, Hansen DK, et al. 2011. Developmental toxicology–
new directions workshop: Refining testing strategies and study
designs. Birth Defects Res B Dev Reprod Toxicol (this issue).
CalEPA (California Environmental Protection Agency). 2003. Proposition
65: Safe Drinking Water and Toxic Enforcement Act of 1986
(Amended August 11, 2003). Sacramento, CA: California Environ-
mental Protection Agency, Office of Environmental Health Hazard
Assessment. Available at: http://www.oehha.org/prop65.html
Carney EW, Ellis AL, Tyl RW, et al. (2011) Critical evaluation of current
developmental toxicity testing strategies: a case of babies and their
bathwater. Birth Defects Res B Dev Reprod Toxicol (this issue).
CDPH. 2005. California Safe Cosmetics Program. Sacramento, CA:
California Department of Public Health, Occupational Health
Branch. Available at: http://www.cdph.ca.gov/programs/cosmetics/
Pages/default.aspx
Collins TFX, Sprando RL, Shackelford ME, et al. 2006. Principles of risk
assessment–FDA perspective. In: Hood RD, editor. Developmental
and reproductive toxicology–a practical approach. 2nd ed.
New York: CRC Press. p 877–909.
Cooper RL, Lamb JC, Barlow SM, et al. 2006. A tiered approach to life
stages testing for agricultural chemical safety assessment. Crit Rev
Toxicol 36:69–98.
CPSC. 1992. Consumer Product Safety Commission, 16 CFR Part 1500
Labeling Requirements for Art Materials Presenting Chronic
Hazards; Guidelines for Determining Chronic Toxicity of Products
Subject to the FHSA; Supplementary Definition of ‘‘Toxic’’ under the
Federal Hazardous Substances Act: Final Rules. Friday, October 9,
1992. Fed Regist 57:46626–46674.
CPSC. 2008a. Consumer Product Safety Act, amended. 15 U.S.C. yy 2051–
2089. Public Law 92–573; 86 Stat. 1207, October 27, 1972. Consumer
Product Safety Commission, Washington, DC. Available at: http://
www.cpsc.gov/about/cpsia/legislation.html
CPSC. 2008b. Consumer Product Safety Improvement Act of 2008. H.R.
4040. Consumer Product Safety Commission, Washington, DC.
Available at: http://www.cpsc.gov/about/cpsia/legislation.html
CPSC. 2008c. Federal Hazardous Substances Act, amended, Consumer
Product Safety Commission, Washington, DC. Available at: http://
www.cpsc.gov/about/cpsia/legislation.html
CVM. 2006. Guidance for Industry x3. General Principles for Evaluating
the Safety of Compounds Used in Food-Producing Animals.
Rockville, MD: FDA Center for Veterinary Medicine. Available
at: http://www.fda.gov/downloads/AnimalVeterinary/Guidance-
ComplianceEnforcement/GuidanceforIndustry/UCM052180.pdf
Dix DJ, Houck KA, Martin MT, et al. 2007. The ToxCast program for
prioritizing toxicity testing of environmental chemicals. Toxicol Sci
95:5–12.
EC (European Communities). 1976. Council Directive 76/768/EEC, OJ L
262, September 27, 1976. p 169.
EC (European Communities). 1989. Council Directive 89/107/EEC, OJ L
40, February 11, 1989. p 27.
EC (European Communities). 2002. Regulation (EC) No 178/2002, OJ L
31, February 1,2002. p 1.
EC (European Communities). 2006. Regulation (EC) No 1907/2006 of the
European Parliament and of the Council of 18 December 2006
concerning the Registration, Evaluation, Authorisation and Restric-
tion of Chemicals (REACh). Available at: http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri5CONSLEG:2006R1907:20071123:EN:pdf
or: http://ec.europa.eu/environment/chemicals/reach/reach_intro.htm
Hatch EE, Palmer JR, Titus-Ernstoff L, et al. 1998. Cancer risk in
women exposed to diethylstilbestrol in utero. J Am Med Assoc
280:630–634.
ICH. 2005. S5(R2). Detection of toxicity to reproduction for medical
products & toxicity to male fertility. ICH Harmonized Tripartite
Guildeline. International Committee on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use,
Geneva, Switzerland. Available at: http://www.ich.org/cache/com-
po/276-254-1.html
ILSI-HESI. 2004. Toxicogenomics database. http://www.hesiglobal.org/
Committees/TechnicalCommittees/Genomics/EBI1Toxicogenomics.
htm
Judson R, Richard A, Dix DJ, et al. 2009. The toxicity data landscape for
environmental chemicals. Environ Health Perspect. 117:685–695.
Knudsen TB, Kavlock RJ, Daston GP, et al. 2011. Developmental toxicity
testing for safety assessment: new approaches and technologies.
Birth Defects Res B Dev Reprod Biol (this issue).
Kweder S. 2008. Drugs and biologics in pregnancy and breastfeeding:
FDA in the 21st century. Birth Defects ResA Clin Mol Teratol 82
(9):605–609.
Lein P, Silbergeld E, Locke P, Goldberg AM. 2005. In vitro and other
alternative approaches to developmental neurotoxicity resting
(DNT). Environ Toxicol Pharmacol 19:735–744.
Makris SL. 2010. EPA and OECD perspectives on reproductive and
developmental toxicity testing. In: Kapp RW, Tyl RW, editor. Reproduc-
tive toxicology. 3rd ed. New York: Informa Healthcare. p 86–108.
Makris SL, Solomon H, Clark R, et al. 2009. Terminology of develop-
mental abnormalities in common laboratory mammals (Version 2).
Birth Defects Research Part B. 86:227–327.
NRC (National Research Council). 2000. Scientific frontiers in develop-
mental toxicology and risk assessment. Washington, DC: National
Academy Press.
NRC (National Research Council). 2007a. Applications of toxico-
genomic technologies to predictive toxicology and risk assessment.
Washington, DC: The National Academies Press.
NRC (National Research Council). 2007b. Toxicity testing in the 21st
century. Washington, DC: The National Academies Press.
NRC (National Research Council). 2008a. Review of federal strategy for
nanotechnology-related environmental, health, and safety research.
Washington, DC: National Academies Press.
NRC (National Research Council). 2008b. Phthalates and Cumulative
Risk Assessment. Washington, DC: The National Academies Press.
NRC (National Research Council). 2009. Science and decisions: advancing
risk assessment. Washington, DC: The National Academies Press.
NTP. 2004a. NTP-CERHR Monograph on the Potential Human Repro-
ductive and Developmental Effects of Ethylene Glycol. NIH
Publication No. 04-4481. Research Triangle Park, NC: Center for
the Evaluation of Risks to Human Reproduction, National Toxicology
Program. Available at: http://cerhr.niehs.nih.gov/chemicals/egpg/
ethylene/eg-eval.html
NTP. 2004b. Toxicology in the 21st century: the role of the national
toxicology program. Available at: http://ntp.niehs.nih.gov/ntp/
main_pages/NTPVision.pdf
OECD. 1983. Test guideline 415. OECD guideline for testing of chemicals.
One-generation reproduction toxicity study. Paris, France: Organisa-
tion of Economic Co-operation and Development. Available at:
http://titania.sourceoecd.org/vl 5 4717558/cl 513/nw51/rpsv/cw/
vhosts/oecdjournals/1607310x/v1n4/contp1-1.htm
OECD. 1995. Test guideline 421. OECD guideline for testing of chemicals.
Reproduction/developmental toxicity screening test. Paris,
France: Organisation of Economic Co-operation and Development.
Available at: http://titania.sourceoecd.org/vl5 4717558/cl5 13/
nw5 1/rpsv/cw/vhosts/oecdjournals/1607310x/v1n4/contp1-1.htm
OECD. 1996. Test guideline 422. OECD guideline for testing of chemicals.
Combined repeated dose toxicity study with the reproduction/
developmental toxicity screening test. Paris, France: Organisation of
Economic Co-operation and Development. Available at: http://
titania.sourceoecd.org/vl54717558/cl513/nw51/rpsv/cw/vhosts/
oecdjournals/1607310x/v1n4/contp1-1.htm
OECD. 2001a. Test guideline 414. OECD guideline for testing of
chemicals. Prenatal developmental toxicity study. Paris, France:
Organisation of Economic Co-operation and Development. Available
at: http://titania.sourceoecd.org/vl5 4717558/cl5 13/nw5 1/rpsv/
cw/vhosts/oecdjournals/1607310x/v1n4/contp1-1.htm
OECD. 2001b. Test guideline 416. OECD guideline for testing of
chemicals. Two-generation reproduction toxicity study. Paris, France:
Organisation of Economic Co-operation and Development. Available
at: http://titania.sourceoecd.org/vl5 4717558/cl5 13/nw5 1/rpsv/
cw/vhosts/oecdjournals/1607310x/v1n4/contp1-1.htm
OECD. 2005. OECD series on testing and assessment, number 34:
guidance document on the validation and international acceptance
of new or updated test methods for hazard assessment. Organisation
for Economic Co-operation and Development. ENV/JM/MONO
(2005)14, August18, 2005, Paris. Available at: http://www.oecd.org/
officialdocuments/displaydocumentpdf/?cote5 env/jm/mono(2005)
14&doclanguage5 en
393CURRENT AND FUTURE NEEDS
Birth Defects Research (Part B) 92:384–394, 2011
OECD. 2007a. Test Guideline 426. OECD Guideline for Testing of
Chemicals. Developmental Neurotoxicity Study. Paris, France:
Organisation of Economic Co-operation and Development. Available
at: http://titania.sourceoecd.org/vl5 4717558/cl5 13/nw5 1/
rpsv/cw/vhosts/oecdjournals/1607310x/v1n4/contp1-1.htm
OECD. 2007b. Series on testing and assessment no. 69, guidance
document on the validation of (quantitative) structure-activity
relationship (Q)SAR models. Organisation for Economic Co-opera-
tion and Development. ENV/JM/MONO(2007)2, February15, 2007,
Paris. Available at: http://www.oecd.org/dataoecd/55/35/
38130292.pdf
OECD. 2008a. OECD Series on testing and assessment, number 43:
guidance document on mammalian reproductive toxicity testing and
assessment. Organisation for Economic Co-operation and Develop-
ment. ENV/JM/MONO(2008)16, July 24, 2008, Paris. Available at:
http://www.olis.oecd.org / olis /2008doc.nsf / linkto /env-jm-mono
(2008)16
OECD. 2008b. Series on testing and assessment no. 88, workshop on
integrated approaches to testing and assessment. Organisation for
Economic Co-operation and Development. ENV/JM/
MONO(2008)10, May 27, 2008, Paris. Available at: http://www.oec-
d.org/dataoecd/45/52/40705314.pdf
Piersma A. 2006. Alternative methods for developmental toxicity testing.
Basic Clin Pharmacol Toxicol 98:427-431.
Schardein JL. 1998. Animal/human concordance. In: Slikker W,
Chang LW, editors. Handbook of developmental neurotoxicology.
San Diego: Academic Press. p 687–708.
Shuey D, Kim JH. Introduction–developmental toxicology–new direc-
tions. Birth Defects Res B Dev Reprod Biol (this issue).
Tyl RW. 2010. FDA and ICH perspectives on reproductive
and developmental toxicity. In: Kapp RW, Tyl RW, editors.
Reproductive toxicology. 3rd ed. New York: Informa Healthcare.
p 68–85.
U.S. EPA (U.S. Environmental Protection Agency). 1991. Guidelines for
Developmental Toxicity Risk Assessment. Office of Research and
Development, Risk Assessment Forum, EPA/600/FR-91/001. Fed
Regist 56:63798–63826.
U.S. EPA. 1998a. OPPTS 870.3700, Prenatal Developmental Toxicity Study,
Health Effects Test Guidelines, EPA 712-C-98-207, Washington, DC.
Available at: http://www.epa.gov/ocspp/pubs/frs/publications/
Test_Guidelines/series870.htm
U.S. EPA. 1998b. OPPTS 870.3800, Reproduction and Fertility Effects,
Health Effects Test Guidelines, EPA 712-C-98-208, Washington, DC.
Available at: http://www.epa.gov/ocspp/pubs/frs/publications/
Test_Guidelines/series870.htm
U.S. EPA. 1998c. OPPTS 870.6300, Developmental Neurotoxicity Study,
Health Effects Test Guidelines, EPA 712-C-98-239, Washington, DC.
Available at: http://www.epa.gov/ocspp/pubs/frs/publications/
Test_Guidelines/series870.htm
U.S. EPA. 2000a. OPPTS 870.3550, Combined Repeated Dose Toxicity
Study with the Reproduction/Developmental Toxicity Screening
Test, Health Effects Test Guidelines, EPA 712-C-00-367, Washington,
DC. Available at: http://www.epa.gov/ocspp/pubs/frs/publica-
tions/Test_Guidelines/series870.htm
U.S. EPA. 2000b. OPPTS 870.3650, Reproduction/Developmental Toxicity
Screening Test, Health Effects Test Guidelines, EPA 712-C-00-368,
Washington, DC. Available at: http://www.epa.gov/ocspp/pubs/
frs/publications/Test_Guidelines/series870.htm
U.S. EPA. 2007. ToxCastt Program. Available at: http://www.epa.gov/
ncct/toxcast/
U.S. FDA. 2000a. Redbook 2000. Toxicological Principles for the Safety
Assessment of Food Ingredients. IV.C.9.a. Guidelines for Reproduc-
tion Studies. College Park, MD: Center for Food Safety and Applied
Nutrition, U.S. Food and Drug Administration. Available at: http://
www.cfsan.fda.gov/Bredbook/redivc9a.html
U.S. FDA. 2000b. Redbook 2000. Toxicological Principles for the Safety
Assessment of Food Ingredients. IV.C.9.b. Guidelines for Develop-
mental Toxicity Studies. College Park, MD: Center for Food Safety
and Applied Nutrition, U.S. Food and Drug Administration.
Available at: http://www.cfsan.fda.gov/Bredbook/redivc9b.html
U.S. FDA. 2002. Guidance for industry: establishing pregnancy exposure
registries. Rockville, MD: Center for Drug Evaluation and Research,
Center for Biologics Evaluation and Research, U.S. Food and Drug
Administration. Availabl at: http://www.fda.gov/cder/guidance/
3626fnl.htm
U.S. FDA. 2004. Challenge and opportunity on the critical path to new
medical products. Rockville, MD: U.S. Department of Health and
Human Services. U.S. Food and Drug Administration. Availabe at:
http: //www.fda.gov /downloads/ScienceResearch/SpecialTopics/
CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm11411.pdf
U.S. FDA. 2005a. FDA authority over cosmetics. College Park, MD:
CFSAN Office of Cosmetics and Colors. Availabe at: http://
www.cfsan.fda.gov/Bdms/cos-206.html
U.S. FDA. 2005b. Guidance for Industry: Pharmacogenomic Data
Submissions. Rockville, MD: Center for Drug Evaluation and
Research, U.S. Food and Drug Administration, Center for Biologics
Evaluation and Research, Center for Devices and Radiological
Health, U.S. Food and Drug Administration. Available at: http://
www.fda.gov/cder/guidance/6400fnl.pdf
U.S. FDA. 2006. Guidance for industry: nonclinical safety evaluation of
pediatric drug products. Rockville, MD: Center for Drug Evaluation
and Research, U.S. Food and Drug Administration. Available at:
http://www.fda.gov/cder/guidance/5671fnl.pdf
U.S. FDA. 2008. Content and format of labeling for human prescription
drug and biological products; requirements for pregnancy and
lactation labeling, proposed rule, May 29, 2008. Fed Regist 73:
30831–30868.
U.S. FDA. 2010. International Cooperation on Cosmetic Regulation
(ICCR). Rockville, MD: International Programs/Harmonization
Initiatives. Available at: http://www.fda.gov/InternationalPro-
grams/HarmonizationInitiatives/ucm114513.htm
U.S. HHS (U.S. Department of Health and Human Services). 2008.
Personalized health care: pioneers, partnerships, progress. Initiative
on personalized health care. Office of the Assistant Secretary for
Planning and Evaluation, Department of Health and Human
Services, Washington, DC. Available at: http://www.hhs.gov/
myhealthcare/news/phc_2008_report.pdf
VICH. 2004a. Studies to evaluate the safety of residues of veterinary
drugs in human food: reproductive toxicity testing (VICH GL22).
Brussels: International Cooperation on Harmonisation of Technical
Requirements for Registration of Veterinary Medical Products.
http://www.vichsec.org/en/guidelines2.htm
VICH. 2004b. Studies to evaluate the safety of residues of veterinary
drugs in human food: developmental toxicity testing (VICH GL32).
Brussels: International Cooperation on Harmonisation of Technical
Requirements for Registration of Veterinary Medical Products.
Available at: http://www.vichsec.org/en/guidelines2.htm
VICH. 2008. Target animal safety for veterinary pharmaceutical products
(VICH GL43). Brussels: International Cooperation on Harmonisation
of Technical Requirements for Registration of Veterinary Medical
Products. Available at: http://www.vichsec.org/en/guidelines2.htm
Wise LD, Beck SL, Beltrame D, et al. 1997. Terminology of developmental
abnormalities in common laboratory mammals (version 1). Teratol-
ogy 55:249–292.
Woodcock J, Woolsey R. 2008. The FDA critical path initiative and its
influence on new drug development. Annu Rev Med 59:1–12.
394 MAKRIS ET AL.
Birth Defects Research (Part B) 92:384–394, 2011
